• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

14.16 +0.25 (+1.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,229,611
Open 13.91
Bid (Size) 14.06 (200)
Ask (Size) 14.16 (100)
Prev. Close 13.91
Today's Range 13.91 - 14.25
52wk Range 13.26 - 50.89
Shares Outstanding 41,833,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
December 23, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 ↗
December 04, 2025
Janux's chief business officer unloaded 16.87% of his direct holdings in a routine insider sale. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+3.7%
+3.7%
1 Month
-9.1%
-9.1%
3 Month
-46.6%
-46.6%
6 Month
-43.7%
-43.7%
1 Year
-69.7%
-69.7%

More News

Read More
News headline image
Which stocks are moving on Tuesday? ↗
December 02, 2025
Via Chartmill
News headline image
Navigating 10 Analyst Ratings For Janux Therapeutics ↗
December 11, 2024
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-12-02: top gainers and losers in today's session. ↗
December 02, 2025
Via Chartmill
News headline image
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
December 02, 2025
Via Stocktwits
News headline image
Which stocks are gapping on Tuesday? ↗
December 02, 2025
Via Chartmill
News headline image
Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗
December 02, 2025
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
December 02, 2025
Via Chartmill
News headline image
What's going on in today's after hours session ↗
December 01, 2025
Via Chartmill
News headline image
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
December 01, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
November 24, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux (JANX) R&D Soars Revenue Misses ↗
August 07, 2025
Via The Motley Fool
News headline image
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 07, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
August 05, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
July 24, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
July 17, 2025
From Janux Therapeutics
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
July 15, 2025
Via Benzinga
News headline image
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
July 11, 2025
Via Benzinga
News headline image
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
May 15, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
May 08, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
May 05, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
From Janux Therapeutics
Via Business Wire
News headline image
The Top 5 Mid Cap Stocks Of 2024 ↗
December 19, 2024
Via Talk Markets
Topics Stocks / Equities

Frequently Asked Questions

Is Janux Therapeutics, Inc. - Common Stock publicly traded?
Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Janux Therapeutics, Inc. - Common Stock trade on?
Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?
The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market
What is the current price of Janux Therapeutics, Inc. - Common Stock?
The current price of Janux Therapeutics, Inc. - Common Stock is 14.16
When was Janux Therapeutics, Inc. - Common Stock last traded?
The last trade of Janux Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?
The market capitalization of Janux Therapeutics, Inc. - Common Stock is 592.36M
How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?
Janux Therapeutics, Inc. - Common Stock has 592M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap